Germany Legal Cannabis Market Report 2025-2030: Competitive Analysis of The Cronos Group, Organigram, Tilray, Canopy Growth, Aurora Cannabis, SynBiotic, Cansativa, Four 20 Pharma, and Avextra Pharma
Germany's legal cannabis market, valued at USD 37.15M in 2024, is expected to reach USD 85.64M by 2030, driven by rising acceptance, medical applications, and tech innovations. Key growth factors include government support, increased medical cannabis use, and advanced cultivation technologies. Ideal for market analysis and strategy planning.
German Legal Cannabis Market
Dublin, June 18, 2025 (GLOBE NEWSWIRE) -- The "Germany Legal Cannabis Market Size, Share & Trends Analysis Report by Source (Hemp, Marijuana), Derivatives (CBD, THC, Others), End-use with Growth Forecasts, Key Companies and Competitive Analysis, 2025-2030" report has been added to ResearchAndMarkets.com's offering.The German Legal Cannabis Market was valued at USD 37.15 million in 2024, and is projected to reach USD 85.64 million by 2030, rising at a CAGR of 14.09%.
Factors such as rising social acceptance of cannabis, growing medical applications of cannabis, increasing R&D & technological innovation, and the introduction of new cultivation technologies are expected to drive the cannabis industry in the country. For instance, in February 2024, according to data published in Reuters, 4.5 million individuals are estimated to use cannabis in Germany. Furthermore, favorable government initiatives and reimbursement policies fuel the market growth. For instance, according to data published by the Federal Union of German Associations of Pharmacists (ABDA), the number of prescriptions for medical cannabis for Statutory Health Insurance (SHI)-insured patients in Germany was 338,500 in 2022. Furthermore, according to the same source, 14,840 Kg of cannabis was delivered to pharmacies for medicinal purposes in 2022.Moreover, growing awareness among people regarding the therapeutic applications of cannabis and the launch of online cannabis prescription platforms drive market growth. For instance, in September 2023, Cantourage Group SE, a Berlin-based company, introduced Telecan, a telemedicine platform for medical cannabis, under the guidance of Florian Wesemann, a medical doctor. The platform offers a simple and convenient way for potential patients to access cannabis therapy.
In recent years, there has been a significant rise in the usage of cannabis and its derivatives in Germany. The medical application of CBD has gained immense popularity, leading to the development of policies for its distribution and use by the government. Moreover, conferences and various events being organized for cannabis industry leaders drive market growth. For instance, the International Cannabis Business Conference was to be held in Berlin in April 2024, Germany's biggest annual gathering of influential political and cannabis business leaders.The cannabis industry has witnessed the development of new techniques and technologies that aid in its cultivation, and these advancements are expected to boost market growth. The demand for technologically advanced cannabis production has led to the optimization of resources by cultivators.
This, coupled with the increased utilization of hemp and marijuana in various sectors, such as personal care & cosmetics, pharmaceuticals, nutraceuticals, and food, & beverages, has impelled market growth. In addition, the use of cannabis and its derivatives by various businesses as a raw material for manufacturing products is projected to drive market growth over the forecast period.Germany Legal Cannabis Market Report Highlights
By source, the hemp segment dominated the market with the highest revenue share of 84.50% in 2024. Hemp covers an extensive range of products, including supplements, nutritional powders, beverages, protein & nutrition bars, animal feed, and pet food.
By derivatives, the CBD segment dominated the market with the largest revenue share of 63.61% in 2024. CBD is the non-psychoactive compound found in the cannabis plant, and its adoption is increasing for a wide range of health benefits.
By end use, the industrial use segment dominated the market with a revenue share of 80.26% in 2024.
This report addresses:
Market intelligence to enable effective decision-making
Market estimates and forecasts from 2018 to 2030
Growth opportunities and trend analyses
Segment and regional revenue forecasts for market assessment
Competition strategy and market share analysis
Product innovation listings for you to stay ahead of the curve
Companies Featured The major companies featured in this Germany Legal Cannabis market report include:
The Cronos Group
Organigram Holding, Inc
Tilray Brands
Canopy Growth Corporation
Aurora Cannabis
SynBiotic
Cansativa GmbH
DEMECAN
Four 20 Pharma
Avextra Pharma
Key Attributes:
Report Attribute
Details
No. of Pages
150
Forecast Period
2024 - 2030
Estimated Market Value (USD) in 2024
$37.15 Million
Forecasted Market Value (USD) by 2030
$85.64 Million
Compound Annual Growth Rate
14.0%
Regions Covered
Germany
Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.3. Competitive InsightsChapter 3. Germany Legal Cannabis Market Variables, Trends, and Scope3.1. Market Lineage Outlook3.2. Germany Legal Cannabis Market - Market Dynamics3.3. Germany Legal Cannabis: Market Analysis Tools3.4. Current Market Trends in Cannabis Industry3.5. Regulatory Scenario3.6. Cannabis Consumption Pattern Analysis3.7. Guidelines and Requirements for Cannabis Cultivation3.8. Cannabis Facility Design and Equipment Requirements3.9. Reimbursement Policies in the GermanyChapter 4. Germany Legal Cannabis Market: Segment Analysis, By Source, 2018-2030 (USD Million)4.1. Definition and Scope4.2. Source Market Share Analysis, 2024 & 20304.3. Segment Dashboard4.4. Germany Legal Cannabis Market, by Source, 2018 to 20304.5. Marijuana4.5.1. Marijuana Market Estimates and Forecasts, 2018-2030 (USD Million)4.5.2. Flower4.5.3. Oil and Tinctures4.6. Hemp4.6.1. Hemp Market Estimates and Forecasts, 2018-2030 (USD Million)4.6.2. Hemp Oil4.6.3. Industrial HempChapter 5. Germany Legal Cannabis Market: Segment Analysis, By Derivative, 2018-2030 (USD Million)5.1. Definition and Scope5.2. Derivative Market Share Analysis, 2024 & 20305.3. Segment Dashboard5.4. Germany Legal Cannabis Market, by Derivative, 2018 to 20305.5. CBD5.6. THC5.7. OthersChapter 6. Germany Legal Cannabis Market: Segment Analysis, By End Use, 2018-2030 (USD Million)6.1. Definition and Scope6.2. End Use Market Share Analysis, 2024 & 20306.3. Segment Dashboard6.4. Germany Legal Cannabis Market, by End Use, 2018 to 20306.5. Medical Use6.5.1. Medical Market Estimates and Forecasts, 2018-2030 (USD Million)6.5.2. Cancer6.5.3. Chronic Pain6.5.4. Depression and Anxiety6.5.5. Arthritis6.5.6. Diabetes6.5.7. Glaucoma6.5.8. Migraines6.5.9. Epilepsy6.5.10. Multiple Sclerosis6.5.11. AIDS6.5.12. Amyotrophic Lateral Sclerosis6.5.13. Alzheimers's6.5.14. Post Traumatic Stress Disorder (PTSD)6.5.15. Parkinson's6.5.16. Tourettes6.5.17. Others6.6. Recreational Use6.7. Industrial UseChapter 7. Germany Legal Cannabis Market: Competitive Landscape7.1. Participant's Categorization7.2. Company Market Position Analysis, 20247.3. Strategy Mapping7.4. Company Profiles
The Cronos Group
Organigram Holding, Inc
Tilray Brands
Canopy Growth Corporation
Aurora Cannabis
SynBiotic
Cansativa GmbH
DEMECAN
Four 20 Pharma
Avextra Pharma
For more information about this report visit https://www.researchandmarkets.com/r/q7s0so
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
German Legal Cannabis Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Exclusive-Indian refiners cancel palm oil orders for July-Sept as prices surge
By Rajendra Jadhav MUMBAI (Reuters) -Indian refiners cancelled orders for 65,000 metric tons of crude palm oil (CPO) scheduled for delivery from July to September following a sudden surge in benchmark Malaysian prices, four trade sources told Reuters. Refiners in the world's largest palm oil importer cancelled the orders in the past three days after Malaysian palm oil futures rose more than 6%, hedging their risk against the prospect of falling prices by locking in a profit. "There is a lot of volatility in the market. There was more margin in cancelling bought CPO than in importing, refining, and selling refined palm oil in the local market," said an Indian buyer who operates a refinery on the west coast and cancelled shipments for July delivery. Indian buyers made CPO purchases nearly a month ago around $1,000 to $1,030 per ton, including cost, insurance, and freight, after a rebound in palm oil production brought down prices to their lowest in more than eight months. This week, palm oil futures jumped, tracking a rally in Chicago soyoil futures after the U.S. proposed higher biofuel blending volumes. The sudden rise prompted Indian refiners to cancel contracts at between $1,050 and $1,065 per ton, making a profit of more than $30 per ton, said the sources who spoke on condition of anonymity because they were not authorised to speak to media. Buyers agreed to contract cancellations by accepting a price slightly lower than the current market rate, a decision mutually reached with sellers, said a New Delhi-based dealer with a global trading house. The CPO is being offered at about $1,070 a ton in India for July delivery, compared to $1,020 to $1,030 a month ago. Despite the cancellations, Indian imports are poised to rise in coming months after falling far below average in recent months, bringing down inventories, said Sandeep Bajoria, chief executive of Sunvin Group, a vegetable oil brokerage. India's palm oil imports hit a six-month high in May, driven by low inventories and the oil's price discount to rival soyoil and sunflower oil. Indian buying had gained momentum after India last month halved the import duty on CPO, but the cancellations have disrupted that momentum, said a Kuala Lumpur-based trader with a palm oil producing company. Sign in to access your portfolio
Yahoo
16 minutes ago
- Yahoo
Hotel groups Hilton and Marriot announce African expansion plans
By Colleen Goko JOHANNESBURG (Reuters) -U.S. hotel chains Hilton and Marriott have announced African expansion drives to tap into the continent's rapid tourism growth. Rising business and leisure travel on the continent has made it increasingly attractive for multinational companies and Hilton said on Wednesday that it plans to more than triple its African portfolio to more than 160 hotels. The company plans to enter Angola, Ghana and Benin for the first time while returning to Madagascar and Tanzania, its statement said without providing a specific time horizon for the expansion plans. Marriott expects to add 50 properties by 2027, it said on Wednesday. Those will include entry into five new countries: Cape Verde, Ivory Coast, the Democratic Republic of Congo, Madagascar and Mauritania. The group's existing African portfolio encompasses nearly 150 properties and 26,000 rooms across 20 countries and 22 brands. Airlines have also increased their African capacity. Emirates now offers 161 weekly flights across Africa, recently adding daily services to Entebbe and Addis Ababa. United Airlines launched a direct Washington-Dakar route in May and Delta will begin a seasonal daily flight to Accra in December. International arrivals to the continent rose 9% year on year in the first quarter of 2025, the United Nations World Tourism Organization says, 16% above the same period of pre-pandemic 2019. That momentum is translating into economic impact. Tourism accounts for between 3% and 7% of gross domestic product in countries such as Kenya, Morocco and South Africa, and up to 15% in tourism-heavy economies such as Namibia, World Bank and national statistics show. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
19 minutes ago
- Yahoo
AbbVie's migraine drug meets main goal in head-to-head study with topiramate
(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment in a head-to head late-stage trial. The U.S. drugmaker has been expanding and banking on its neuroscience portfolio after its blockbuster arthritis drug Humira began facing competition from several less expensive biosimilar versions. The study's main goal was for the company's drug Qulipta, also known as Aquipta in Europe, to show a lower discontinuation rate due to undesired effect from the treatment than topiramate. Qulipta was stopped in 12.1% of patients, compared to 29.6% for the generic at 24 weeks. The European Medicines Agency's safety committee had in 2023 recommended pregnant women not use topiramate-containing medicines to prevent migraine or manage their body weight as their newborns could have a higher risk of neurodevelopmental disorders. AbbVie's study also met all secondary goals, with 64.1% patients on Qulipta seeing a 50% or more reduction in the average number of days per month when they experience migraine headaches. In comparison, 39.3% patients on topiramate saw a similar reduction. Qulipta, first approved in the United States in 2021, brought in $658 million in international sales last year.
